MYO5A::FGFR1
represents a novel fusion event in pediatric low-grade glioma
Neurooncol Adv
.
2023 Feb 23;5(1):vdad017.
doi: 10.1093/noajnl/vdad017.
eCollection 2023 Jan-Dec.
Authors
Robert T Galvin
1
,
Cynthia Zheng
2
,
Garrett Fitzpatrick
3
,
Colleen L Forster
3
,
Carolina Sandoval-Garcia
4
,
Daniel Guillaume
4
,
Ahmed Elbermawy
4
,
Andrew C Nelson
3
,
Can Özütemiz
5
,
Liam Chen
3
,
Christopher L Moertel
1
Affiliations
1
Division of Pediatric Hematology and Oncology and Bone Marrow Transplant, University of Minnesota, Minneapolis, MN, USA.
2
University of Minnesota Medical School, Minneapolis, MN, USA.
3
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
4
Department of Neurosurgery, University of Minnesota, Minneapolis, MN, USA.
5
Department of Radiology, University of Minnesota Medical School, Minneapolis, MN, USA.
PMID:
37025756
PMCID:
PMC10072188
DOI:
10.1093/noajnl/vdad017
No abstract available
Keywords:
MYO5A:FGFR1; low-grade glioma; next generation sequencing; pediatric.
Grants and funding
T32 CA099936/CA/NCI NIH HHS/United States